Transforming growth factor‐β1 causes transcriptional activation of CD34 and preserves haematopoietic stem/progenitor cell activity

Summary. Stem/progenitor cells endowed with in vitro and in vivo haematopoietic activity express the surface protein CD34. Transforming growth factor β1 (TGF‐β1) is one of the soluble molecules that regulate cell cycle and differentiation of haematopoietic cells, but has pleiotropic activities depending on the state of responsiveness of the target cells. It has previously been shown that TGF‐β1 maintains human CD34+ haematopoietic progenitors in an undifferentiated state, independently of any cell cycle effect. Here, we have shown that TGF‐β1 upregulates the human CD34, an effect that was evident in primary stem/progenitor cells (CD34+lin–) both at the transcriptional and protein levels, and was not associated with any relevant effect on cell growth. The presence of TGF‐β1 influenced differentiation, maintaining primary CD34+/Lin– in an undifferentiated state. This effect was associated with Smad activation and with a dramatic decrease in p38 phosphorylation. Moreover, blocking p38 phosphorylation by the SB202190 inhibitor increased CD34 RNA levels but did not enhance CD34 protein expression in CD34+/Lin– cells, suggesting that modulation of multiple signalling pathways is necessary to reproduce TGF‐β1 effects. These data establish the role that TGF‐β1 has in the modulation of the CD34 stem/progenitor protein and stem/progenitor functions, providing important clues for understanding haematopoietic development and a potential tool for the modulation of human haematopoiesis.

[1]  W. Vainchenker,et al.  Stromal cells retard the differentiation of CD34(+)CD38(low/neg) human primitive progenitors exposed to cytokines independent of their mitotic history. , 2001, Blood.

[2]  C. Eaves,et al.  SDF-1 And tgf-β enhance the detection of transplantable human stem cells regenerating in nod/scid mice , 2000 .

[3]  S. Rutella,et al.  Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-beta1 is a cell cycle-independent effect and influences their hematopoietic potential. , 2000, Blood.

[4]  S. Rutella,et al.  CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/− precursors , 2000, British journal of haematology.

[5]  S. Sebti,et al.  TGF-beta1 stimulation of fibronectin transcription in cultured human lung fibroblasts requires active geranylgeranyl transferase I, phosphatidylcholine-specific phospholipase C, protein kinase C-delta, and p38, but not erk1/erk2. , 2000, Archives of biochemistry and biophysics.

[6]  N. Fortunel,et al.  TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. , 2000, Journal of cell science.

[7]  Jiahuai Han,et al.  Transforming Growth Factor-β Induces Collagenase-3 Expression by Human Gingival Fibroblasts via p38 Mitogen-activated Protein Kinase* , 1999, The Journal of Biological Chemistry.

[8]  K. Ando,et al.  Ex vivo generation of CD34(+) cells from CD34(-) hematopoietic cells. , 1999, Blood.

[9]  D. Tenen,et al.  A nuclear factor Y (NFY) site positively regulates the human CD34 stem cell gene. , 1999, Blood.

[10]  E. Nishida,et al.  Involvement of the p38 Mitogen-activated Protein Kinase Pathway in Transforming Growth Factor-β-induced Gene Expression* , 1999, The Journal of Biological Chemistry.

[11]  A. Fattorossi,et al.  Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15. , 1999, Experimental hematology.

[12]  W. May,et al.  CD34 expression by embryonic hematopoietic and endothelial cells does not require c-Myb. , 1998, Experimental hematology.

[13]  Y Nagata,et al.  Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. , 1998, Blood.

[14]  J. Dick,et al.  A newly discovered class of human hematopoietic cells with SCID-repopulating activity , 1998, Nature Medicine.

[15]  A. Fattorossi,et al.  Functional, phenotypic and molecular characterization of cytokine low‐responding circulating CD34+ haemopoietic progenitors , 1998, British journal of haematology.

[16]  J. Massagué,et al.  Determinants of specificity in TGF-beta signal transduction. , 1998, Genes & development.

[17]  C. Eaves,et al.  Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential. , 1998, Blood.

[18]  M. Marone,et al.  bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  A. Bellacosa,et al.  Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression , 1998, International journal of cancer.

[20]  K. Weinberg,et al.  A Novel, Myeloid Transcription Factor, C/EBPε, Is Upregulated During Granulocytic, But Not Monocytic, Differentiation , 1997 .

[21]  E. Nishida,et al.  Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. , 1997, Blood.

[22]  K. Miyazono.  TGF-beta receptors and signal transduction. , 1997, International journal of hematology.

[23]  P. Lastres,et al.  Endoglin modulates cellular responses to TGF-beta 1 , 1996, The Journal of cell biology.

[24]  H. Broxmeyer,et al.  Hematopoietic defects in mice lacking the sialomucin CD34. , 1996, Blood.

[25]  M. Greaves,et al.  The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  I. Jinnai,et al.  Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation. , 1995, Experimental hematology.

[27]  M. Fackler,et al.  Full-length but not truncated CD34 inhibits hematopoietic cell differentiation of M1 cells. , 1995, Blood.

[28]  K. Riabowol,et al.  Monitoring mRNA expression by polymerase chain reaction: the "primer-dropping" method. , 1994, Analytical biochemistry.

[29]  B. Calabretta,et al.  Ets-2 and c-Myb act independently in regulating expression of the hematopoietic stem cell antigen CD34. , 1994, The Journal of biological chemistry.

[30]  B. Calabretta,et al.  Regulation of the expression of the hematopoietic stem cell antigen CD34: role of c-myb , 1994, The Journal of experimental medicine.

[31]  M. Fackler,et al.  Up-regulation of surface CD34 is associated with protein kinase C-mediated hyperphosphorylation of CD34. , 1992, The Journal of biological chemistry.

[32]  D. Tenen,et al.  Regulation of the gene for CD34, a human hematopoietic stem cell antigen, in KG-1 cells. , 1990, Blood.

[33]  S. Rutella,et al.  Transforming growth factor-β1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects , 2002, Leukemia.

[34]  N. Fortunel,et al.  Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. , 2000, Blood.

[35]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[36]  M. Fackler,et al.  CD34: structure, biology, and clinical utility. , 1996, Blood.

[37]  A. Bloch,et al.  Regulation of c-myb expression in ML-1 human myeloblastic leukemia cells by c-ets-1 protein. , 1995, Advances in enzyme regulation.

[38]  J. Massagué,et al.  The transforming growth factor-beta family. , 1990, Annual review of cell biology.